Biomerieux, Inc.

Hospices Civils De Lyon

Universite Claude Bernard – Lyon1

Centre Hospitalier Universitaire De Nantes

Université Claude Bernard

Université Claude Bernard Lyon I

Bioaster

Fabienne Venet

Guillaume Monneret

Alain Lepape

François Mallet

Julien Textoris

Estelle Peronnet

Astrid Villars

Benjamin Delwarde

Elisabeth Cerrato

Tanguy Fortin

Alexandre Pachot

Karim Asehnoune

Sylvie Pons

Marilyne Dupin

Maud Tournoud

Marie-Angelique Cazalis

Antoine Roquilly

Virginie Moucadel

Marie-Angélique Cazalis

Julie Demaret

Audrey Larue-Triolet

Aurélie Gouel-Cheron

Bernard Allaouchiche

Astrid Villars-Mechin

Thomas Rimmelé

Laurence Vachot

A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.

Kit for assessing the risk of complications in patients with systemic inflammatory response syndrome (SIRS)

The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.

Method and kit for making an in vitro prognosis of severity for a patient in septic shock

The invention concerns a method of in vitro or ex vivo evaluation of the risk of complications in a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, the method being characterized in that it comprises the step of detecting, in a biological sample obtained from said patient, at least one transcript of the IL7R gene, as well as measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene, in a biological sample from a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, in order to evaluate the risk of complications, and in particular of mortality, in said patient. The invention also concerns kits for measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene in a biological sample.

Method for assessing the risk of complications in patients with systemic inflammatory response syndrome (sirs)

A kit for in vitro or ex vivo measurement of sCD127 expression in a biological sample, the kit including:

Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample

The invention provides a method of evaluating the risk of mortality in patients who present a systemic inflammatory response (SIRS) or septic syndromes, comprising measuring the expression of sCD127 in a biological sample.

Method for evaluating the risk of mortality in patients who exhibit a systemic inflammatory response syndrome (SIRS) or sepsis

A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a &#x394; value; and comparing the &#x394; value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Prediction of the risk of developing a disseminated infection for patients admitted to an intensive care unit

The invention relates to a process for determining the susceptibility to nosocomical infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample.

Process for determining the susceptibility to nosocomial infections

Growing community of inventors

Lyons, France

Fabienne Venet